Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
5(50%)
Results Posted
100%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
1
10%
Ph phase_4
1
10%
Ph phase_1
8
80%

Phase Distribution

8

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
8(80.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(6)
Completed(1)
Terminated(3)

Detailed Status

Recruiting5
Withdrawn2
Completed1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 18 (80.0%)
Phase 21 (10.0%)
Phase 41 (10.0%)

Trials by Status

completed110%
withdrawn220%
not_yet_recruiting110%
recruiting550%
terminated110%

Recent Activity

5 active trials
Showing 5 of 10
recruitingphase_2

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

NCT07304739
recruitingphase_4

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

NCT06230055
not_yet_recruitingphase_1

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT07175415
recruitingphase_1

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05751044
recruitingphase_1

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05745714
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07304739Phase 2

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Recruiting
NCT06230055Phase 4

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

Recruiting
NCT07175415Phase 1

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Not Yet Recruiting
NCT05751044Phase 1

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Recruiting
NCT05745714Phase 1

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Recruiting
NCT05658640Phase 1

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

Recruiting
NCT05521087Phase 1

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Withdrawn
NCT04029688Phase 1

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Terminated
NCT05740449Phase 1

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Withdrawn
NCT01324180Phase 1

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10